AB0336 COMPARATIVE ANALYSIS OF ESTIMATED BONE MASS AND BONE MINERAL DENSITY IN PATIENTS WITH RHEUMATOID ARTHRITIS FROM THE CHIKARA STUDY. (June 2019)

• Record Type: Journal Article
• Authors: Mandai, Koji; Yamada, Yutaro; Koike, Tatsuya; Okano, Tadashi; Hidaka, Noriaki; Tada, Masahiro
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 1625
• Page End: 1626
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.1486
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Patients with rheumatoid arthritis (RA) have lower muscle mass and a higher rate of sarcopenia than healthy individuals. The relationship between rheumatoid arthritis and bone loss is well known. Dual energy X-ray absorptiometry (DEXA) and bioelectrical impedance analysis (BIA) are used to diagnose sarcopenia, but the correlation between bone mineral density and estimated bone mass is unknown. Objectives: To investigate the correlation between bone mineral density and bone mass in RA patients. Methods: Data from a prospective observational study (CHIKARA study) were analyzed. Bone mineral density (BMD) was measured by DEXA, and bone mass was measured by BIA on the same day, and the correlations between BMD at each measurement site and bone mass were evaluated. Results: A total of 90 RA patients (women, 83%; mean age, 67.2±12.1 years) were included. The median disease duration was 8.5 (interquartile range (IQR): 4.9, 17) years, the mean DAS28-ESR was 2.92±1.2, and the median MTX dose was 10 (IQR: 8, 12) mg/week. Nineteen patients (21%) used a biologic agent. There was a significant correlation between total hip BMD and bone mass (r=0.64, p<0.001). The details are shown in Figure 1 . Bone mass was significantly correlated with femoral neck BMD (r=0.62, p<0.001), whole body BMD (r=0.60, p<0.001), and lumbar BMD (r=0.49, p<0.001). Bone mass was significantly lower by DEXA (1.9±0.5 kg) than by BIA (2.0±0.4 kg) (P<0.001). Conclusion: There was a significant correlation between bone mass by BIA and BMD by DEXA. Bone mass by BIA and total hip BMD had the strongest correlation. Bone mass is likely to be overestimated by BIA. Thus, we need to evaluate it with appropriate caution. Disclosure of Interests: Koji Mandai: None declared, Yutaro Yamada Speakers bureau: Abbvie, Chugai, Mitsubishi Tanabe, Tatsuya Koike Speakers bureau: AbbVie, Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Janssen, Lilly, Mitsubishi Tanabe Pharma Corporation, MSD, Ono Pharmaceutical, Pfizer, Roche, Takeda Pharmaceutical, Teijin Pharma, and UCB, Tadashi Okano Speakers bureau: AbbVie, Noriaki Hidaka: None declared, Masahiro Tada Speakers bureau: Abbvie, Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical, Pfizer Japan, Takeda Pharmaceutical